Shikonin as a therapeutic agent in renal cell carcinoma: insights from TEK-related causal association with glaucoma

TL;DR

This study explores the link between glaucoma and kidney cancer, finding that a compound called shikonin may help treat kidney cancer by targeting shared genes.

Contribution

The study identifies shikonin as a novel therapeutic agent targeting TEK and AKT/mTOR signaling in RCC.

Findings

MR analysis shows a significant causal link between glaucoma and RCC.

Shikonin upregulates TEK and inhibits RCC cell proliferation and migration.

Shikonin suppresses AKT/mTOR phosphorylation in RCC cells.

Abstract

Renal cell carcinoma (RCC) is a lethal malignancy with rising incidence, while glaucoma, a chronic eye disease, shares systemic mechanisms such as oxidative stress and inflammation with cancers. This study aimed to investigate the causal link between glaucoma and RCC and explore molecular intersections to identify novel therapeutic targets.

A two-step Mendelian randomization (MR) analysis using genetic data from the NHGRI-EBI GWAS Catalog and FinnGen database was performed, supplemented by NHANES data. Gene expression analysis (GSE53757, E-MTAB-1980) identified glaucoma-related genes in RCC. Molecular docking and functional assays evaluated shikonin's effects on TEK and AKT/mTOR signaling.

MR revealed a significant causal relationship between glaucoma and RCC. TEK, a glaucoma-related gene, was downregulated in RCC tissues and correlated with advanced tumor stage and metastasis. Shikonin and acetylshikonin upregulated TEK expression, inhibited RCC cell proliferation/migration, and suppressed AKT/mTOR phosphorylation.

These findings support a role for glaucoma-associated genes in RCC development and progression, highlighting shikonin as a promising therapeutic agent targeting this molecular axis.

Figures